BofA/Merrill Lynch Upgrades Qiagen NV (QGEN) to Neutral

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. HUBS
2. BROS
3. FIS
4. ARM
5. EXPE
6. QCOM
7. DDOG
8. PAYC
9. CHYM
10. CPAY

Go back to BofA/Merrill Lynch Upgrades Qiagen NV (QGEN) to Neutral

Qiagen (QGEN) Tops Q3 EPS by 1c, Offers Outlook

November 2, 2016 4:05 PM EDT

Qiagen (NASDAQ: QGEN) reported Q3 EPS of $0.29, $0.01 better than the analyst estimate of $0.28. Revenue for the quarter came in at $338.7 million versus the consensus estimate of $336.04 million.

2016 outlook For the full-year 2016, QIAGEN continues to expect sales growth of about 6-7% CER, which is based on achieving the prior guidance (January 2016) for about 6% CER growth and the addition of about $10 million of first-time sales during the second half of the year from the Exiqon acquisition. About one percentage point of total CER growth is expected from the MO BIO acquisition (December 2015) and about five... More